O	0	7	Soluble
O	8	13	human
O	14	23	epidermal
O	24	30	growth
O	31	37	factor
O	38	46	receptor
O	47	48	2
O	49	50	(
O	50	54	HER2
O	54	55	)
O	56	62	levels
O	63	65	in
O	66	74	patients
O	75	79	with
O	80	84	HER2
O	84	85	-
O	85	93	positive
O	94	100	breast
O	101	107	cancer
O	108	117	receiving
B-intervention	118	130	chemotherapy
I-intervention	131	135	with
I-intervention	136	138	or
I-intervention	139	146	without
I-intervention	147	158	trastuzumab
O	158	159	:
O	160	167	results
O	168	172	from
O	173	178	North
O	179	186	Central
O	187	193	Cancer
O	194	203	Treatment
O	204	209	Group
O	210	218	adjuvant
O	219	224	trial
O	225	230	N9831
O	230	231	.

O	232	241	Increased
O	242	249	soluble
O	250	255	human
O	256	265	epidermal
O	266	272	growth
O	273	279	factor
O	280	288	receptor
O	289	290	2
O	291	292	(
O	292	297	sHER2
O	297	298	)
O	299	301	is
O	302	304	an
O	305	314	indicator
O	315	317	of
O	318	319	a
O	320	324	poor
O	325	334	prognosis
O	335	337	in
O	338	342	HER2
O	342	343	-
O	343	351	positive
O	352	362	metastatic
O	363	369	breast
O	370	376	cancer
O	376	377	.

O	378	380	In
O	381	385	this
O	386	391	study
O	391	392	,
O	393	396	the
O	397	404	authors
O	405	414	evaluated
O	415	421	levels
O	422	424	of
O	425	430	sHER2
O	431	437	during
O	438	447	treatment
O	448	451	and
O	452	454	at
O	455	458	the
O	459	463	time
O	464	466	of
O	467	474	disease
O	475	485	recurrence
O	486	488	in
O	489	492	the
O	493	501	adjuvant
O	502	507	North
O	508	515	Central
O	516	522	Cancer
O	523	532	Treatment
O	533	538	Group
O	539	544	N9831
O	545	553	clinical
O	554	559	trial
O	559	560	.

O	561	564	The
O	565	575	objectives
O	576	580	were
O	581	583	to
O	584	592	describe
O	593	598	sHER2
O	599	605	levels
O	606	612	during
O	613	622	treatment
O	623	626	and
O	627	629	at
O	630	633	the
O	634	638	time
O	639	641	of
O	642	652	recurrence
O	653	655	in
O	656	664	patients
O	665	668	who
O	669	673	were
O	674	684	randomized
O	685	687	to
O	688	697	treatment
O	698	702	arms
O	703	704	A
O	705	706	(
B-control	706	714	standard
I-control	715	727	chemotherapy
O	727	728	)
O	728	729	,
O	730	731	B
O	732	733	(
O	733	741	standard
O	742	754	chemotherapy
O	755	759	with
O	760	770	sequential
O	771	782	trastuzumab
O	782	783	)
O	783	784	,
O	785	788	and
O	789	790	C
O	791	792	(
O	792	800	standard
O	801	813	chemotherapy
O	814	818	with
O	819	829	concurrent
O	830	841	trastuzumab
O	841	842	)
O	842	843	.

O	844	852	Baseline
O	853	860	samples
O	861	865	were
O	866	875	available
O	876	880	from
B-total-participants	881	885	2318
O	886	894	patients
O	894	895	,
O	896	902	serial
O	903	910	samples
O	911	915	were
O	916	925	available
O	926	930	from
O	931	934	105
O	935	943	patients
O	943	944	,
O	945	948	and
O	949	959	recurrence
O	960	967	samples
O	968	972	were
O	973	982	available
O	983	987	from
O	988	991	124
O	992	1000	patients
O	1000	1001	.

O	1002	1005	The
O	1006	1012	cutoff
O	1013	1018	sHER2
O	1019	1024	value
O	1025	1028	for
O	1029	1032	the
O	1033	1038	assay
O	1039	1042	was
O	1043	1045	15
O	1046	1048	ng
O	1048	1049	/
O	1049	1051	mL
O	1051	1052	.

O	1053	1064	Statistical
O	1065	1072	methods
O	1073	1081	included
O	1082	1090	repeated
O	1091	1099	measures
O	1100	1106	linear
O	1107	1113	models
O	1113	1114	,
O	1115	1123	Wilcoxon
O	1124	1128	rank
O	1128	1129	-
O	1129	1132	sum
O	1133	1138	tests
O	1138	1139	,
O	1140	1143	and
O	1144	1147	Cox
O	1148	1158	regression
O	1159	1165	models
O	1165	1166	.

O	1167	1172	There
O	1173	1177	were
O	1178	1189	differences
O	1190	1197	between
O	1198	1204	groups
O	1205	1207	in
O	1208	1213	terms
O	1214	1216	of
O	1217	1220	age
O	1220	1221	,
O	1222	1232	menopausal
O	1233	1239	status
O	1239	1240	,
O	1241	1244	and
O	1245	1252	hormone
O	1253	1261	receptor
O	1262	1268	status
O	1268	1269	.

O	1270	1276	Within
O	1277	1286	treatment
O	1287	1291	arms
O	1292	1293	A
O	1293	1294	,
O	1295	1296	B
O	1296	1297	,
O	1298	1301	and
O	1302	1303	C
O	1303	1304	,
O	1305	1313	patients
O	1314	1317	who
O	1318	1321	had
O	1322	1330	baseline
O	1331	1336	sHER2
O	1337	1343	levels
O	1344	1345	≥
O	1345	1347	15
O	1348	1350	ng
O	1350	1351	/
O	1351	1353	mL
O	1354	1357	had
O	1358	1363	worse
B-outcome	1364	1371	disease
I-outcome	1371	1372	-
I-outcome	1372	1376	free
I-outcome	1377	1385	survival
O	1386	1390	than
O	1391	1399	patients
O	1400	1403	who
O	1404	1407	had
O	1408	1416	baseline
O	1417	1422	sHER2
O	1423	1429	levels
O	1430	1431	<
O	1431	1433	15
O	1434	1436	ng
O	1436	1437	/
O	1437	1439	mL
O	1440	1441	(
O	1441	1444	arm
O	1445	1446	A
O	1446	1447	:
O	1448	1454	hazard
O	1455	1460	ratio
O	1460	1461	,
O	1462	1463	1
O	1463	1464	.
O	1464	1466	81
O	1466	1467	;
O	1468	1469	P
O	1470	1471	=
O	1472	1473	.
O	1473	1477	0014
O	1477	1478	;
O	1479	1482	arm
O	1483	1484	B
O	1484	1485	:
O	1486	1492	hazard
O	1493	1498	ratio
O	1498	1499	,
O	1500	1501	2
O	1501	1502	.
O	1502	1504	08
O	1504	1505	;
O	1506	1507	P
O	1508	1509	=
O	1510	1511	.
O	1511	1515	0015
O	1515	1516	;
O	1517	1520	arm
O	1521	1522	C
O	1522	1523	:
O	1524	1530	hazard
O	1531	1536	ratio
O	1536	1537	,
O	1538	1539	1
O	1539	1540	.
O	1540	1542	96
O	1542	1543	;
O	1544	1545	P
O	1546	1547	=
O	1548	1549	.
O	1549	1551	01
O	1551	1552	)
O	1552	1553	.

O	1554	1559	Among
O	1560	1563	the
O	1564	1567	124
O	1568	1576	patients
O	1577	1580	who
O	1581	1592	experienced
O	1593	1600	disease
O	1601	1611	recurrence
O	1611	1612	,
B-outcome	1613	1618	sHER2
I-outcome	1619	1625	levels
O	1626	1635	increased
O	1636	1640	from
O	1641	1649	baseline
O	1650	1652	to
O	1653	1656	the
O	1657	1661	time
O	1662	1664	of
O	1665	1675	recurrence
O	1676	1678	in
O	1679	1683	arms
O	1684	1685	A
O	1686	1689	and
O	1690	1691	B
O	1692	1695	but
O	1696	1704	remained
O	1705	1714	unchanged
O	1715	1717	in
O	1718	1721	arm
O	1722	1723	C
O	1723	1724	.

O	1725	1733	Patients
O	1734	1737	who
O	1738	1741	had
O	1742	1752	recurrence
O	1753	1758	sHER2
O	1759	1765	levels
O	1766	1767	≥
O	1767	1769	15
O	1770	1772	ng
O	1772	1773	/
O	1773	1775	mL
O	1776	1779	had
O	1780	1781	a
O	1782	1789	shorter
B-outcome	1790	1798	survival
I-outcome	1799	1804	after
I-outcome	1805	1815	recurrence
O	1816	1820	with
O	1821	1822	a
B-outcome	1823	1824	3
I-outcome	1824	1825	-
I-outcome	1825	1829	year
I-outcome	1830	1837	overall
I-outcome	1838	1846	survival
I-outcome	1847	1851	rate
O	1852	1854	of
O	1855	1857	51
O	1857	1858	%
O	1859	1867	compared
O	1868	1872	with
O	1873	1875	77
O	1875	1876	%
O	1877	1880	for
O	1881	1886	those
O	1887	1890	who
O	1891	1894	had
O	1895	1905	recurrence
O	1906	1911	sHER2
O	1912	1918	levels
O	1919	1920	<
O	1920	1922	15
O	1923	1925	ng
O	1925	1926	/
O	1926	1928	mL
O	1929	1930	(
O	1930	1936	hazard
O	1937	1942	ratio
O	1942	1943	,
O	1944	1945	2
O	1945	1946	.
O	1946	1948	36
O	1948	1949	;
O	1950	1952	95
O	1952	1953	%
O	1954	1964	confidence
O	1965	1973	interval
O	1973	1974	,
O	1975	1976	1
O	1976	1977	.
O	1977	1979	19
O	1979	1980	-
O	1980	1981	4
O	1981	1982	.
O	1982	1984	70
O	1984	1985	;
O	1986	1987	P
O	1988	1989	=
O	1990	1991	.
O	1991	1993	01
O	1993	1994	)
O	1994	1995	.

O	1996	1998	In
O	1999	2007	patients
O	2008	2012	with
O	2013	2018	early
O	2019	2024	stage
O	2024	2025	,
O	2026	2030	HER2
O	2030	2031	-
O	2031	2039	positive
O	2040	2046	breast
O	2047	2053	cancer
O	2053	2054	,
O	2055	2056	a
O	2057	2061	high
O	2062	2070	baseline
O	2071	2076	sHER2
O	2077	2082	level
O	2083	2086	was
O	2087	2097	identified
O	2098	2100	as
O	2101	2102	a
O	2103	2113	prognostic
O	2114	2120	marker
O	2121	2131	associated
O	2132	2136	with
O	2137	2144	shorter
O	2145	2152	disease
O	2152	2153	-
O	2153	2157	free
O	2158	2166	survival
O	2166	2167	,
O	2168	2171	and
O	2172	2173	a
O	2174	2178	high
O	2179	2184	sHER2
O	2185	2190	level
O	2191	2193	at
O	2194	2204	recurrence
O	2205	2208	was
O	2209	2219	predictive
O	2220	2222	of
O	2223	2230	shorter
O	2231	2239	survival
O	2239	2240	.
